Biology Matters: Solving Chronic Disease

 If you or someone you know are experiencing long COVID, visit https://precisionlife.com/longcovid?utm_source=podcast&utm_medium=show-notes&utm_campaign=biology-matters-show to learn about the Post COVID DNA Wellness Report - a new personalized genetic report that compares your DNA with thousands of genetic patterns seen in people with long COVID that have been discovered in world leading long COVID research. Be seen, be informed, and have confidence about how to approach your health and well-being with research-based genetic insights.

Long COVID and ME/CFS present a major challenge for medical research: the same diagnostic label can encompass patients with very different symptoms, biological mechanisms, and treatment responses.

In this episode of Biology Matters: Solving Chronic Disease, PrecisionLife CEO Steve Gardner and Co-Founder Rowan Gardner reflect on five years of research into long COVID and ME/CFS and what that work has revealed about the biology underlying these conditions.

They discuss why these diseases are polygenic and heterogeneous, why traditional approaches that focus on individual genetic variants can struggle to capture that complexity, and how analysing combinations of genetic variants can help identify biological mechanisms across patient populations.

The conversation also explores reproducibility, including the testing of genetic findings in independent populations, and what the overlap between long COVID and ME/CFS can reveal about their shared and distinct biology.

Crucially, the discussion moves beyond discovery to ask what these findings could make possible for patients. If biologically distinct patient groups respond differently to treatment, understanding those groups could help researchers design more targeted clinical trials and investigate drug repurposing in more focused populations.

The episode also introduces PrecisionLife’s Post COVID DNA Wellness Report, which makes findings from its long COVID research available to individuals as general wellness and educational information. 


If you or someone you know is experiencing long COVID, learn more about the Post COVID DNA Wellness Report here:
https://precisionlife.com/longcovid

The Post COVID DNA Wellness Report provides general wellness and educational information based on findings from PrecisionLife’s long COVID research. It is not a diagnostic or clinical test and does not provide medical advice.


What You'll Learn

• Why long COVID and ME/CFS are polygenic and heterogeneous rather than single-mechanism diseases
• Why traditional approaches focused on individual genetic variants can struggle with complex chronic disease
• How analysing combinations of genetic variants can help identify biological mechanisms
• How genetic findings identified in one population were tested for reproducibility in independent populations
• What 76 genes shared between long COVID and ME/CFS may reveal about their common and distinct biology
• How LOCOME, DecodeME, Action for ME and patient involvement shaped the research
• Why biological heterogeneity can make treatment effects harder to identify in clinical trials
• How genetic stratification could support smaller, more targeted drug repurposing studies
• What the Post COVID DNA Wellness Report examines, and what it does not claim to do
• Why the next stage of long COVID research is about translating biological understanding into potential patient impact
  
  

About Rowan

Rowan Gardner is Chief Business and Investment Officer and Co-Founder of PrecisionLife, bringing 30+ years of experience across health tech, digital health, deep tech and biotech. Her expertise spans venture funding, strategic partnerships and translating breakthrough science into real-world healthcare impact across multiple continents.

At PrecisionLife, Rowan focuses on how better biological understanding, patient stratification and mechanism-based insights can help healthcare move from broad diagnostic labels toward earlier diagnosis, more precise treatment selection and more effective chronic disease management.

About Steve

Steve Gardner is CEO and Co-Founder of PrecisionLife, recognised for his expertise in mechanism-based biology and its application to complex chronic disease. With more than 25 years of experience across life sciences, informatics and drug discovery, he has contributed to major genomics initiatives and led the development of technologies designed to uncover disease mechanisms in heterogeneous patient populations.
At PrecisionLife, Steve focuses on moving beyond single-gene and broad diagnostic approaches to identify combinations of biological drivers that may explain why patients with the same condition experience different symptoms and treatment responses. His work spans long COVID, ME/CFS and dozens of other complex chronic diseases.
Episode Resources:
Rowan Gardner on LinkedInSteve Gardner Website
PrecisionLife WebsitePost COVID DNA Wellness Report

 Biology Matters is handcrafted by our friends over at: fame.so

The promise of precision medicine is simple to state and difficult to deliver: the right treatment, for the right patient, at the right time. One of the challenges is that researchers often lack access to biological data that can be linked to what happens to patients over time. 

Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, has spent much of his career working on one of the rate-limiting factors behind that promise: access to consented biospecimens that can be linked to longitudinal clinical outcomes.

In this episode of Biology Matters, Rowan Gardner speaks with Barry about how Ovation’s approach to multi-omic human biobanking is designed to meet patients where they already are in healthcare. Instead of relying only on large, all-comers biobanks or slow prospective trials, Ovation works with real-world clinical networks to connect consented samples with health records, allowing researchers to build focused disease cohorts more quickly and study how patients actually progress and respond in routine care.


What You'll Learn:

• Why longitudinal clinical records can make biobanks more powerful for precision medicine
• How “meeting patients where they are” can reduce friction in real-world data generation
• Why GLP-1 response is a major test case for precision medicine in chronic disease
• Why weight loss and blood sugar control may involve different biological mechanisms
• How multi-omic data can support better patient stratification and clinical trial design
• Why precision medicine should improve access to effective therapies, not restrict it
• Why data sovereignty and insight portability can coexist in global precision medicine
• How clinical data could create a feedback loop between research, treatment and patient outcomes
  
  

About Rowan
Rowan Gardner is Chief Business and Investment Officer and Co-Founder of PrecisionLife, bringing 30+ years of experience across health tech, digital health, deep tech and biotech. Her expertise spans venture funding, strategic partnerships and translating breakthrough science into real-world healthcare impact across multiple continents.

At PrecisionLife, Rowan focuses on how better biological understanding, patient stratification and mechanism-based insights can help healthcare move from broad diagnostic labels toward earlier diagnosis, more precise treatment selection and more effective chronic disease management.


About Barry

Barry Wark is Co-Founder and Chief Strategy Officer of Ovation, a multi-omic human biobank company focused on accelerating precision medicine through consented biospecimens linked to longitudinal clinical outcomes. He holds a degree in Symbolic Systems from Stanford University and a PhD in Neurobiology and Behavior from the University of Washington.

Barry’s work sits at the intersection of life science data, translational research and precision medicine infrastructure. His early experience in research data management showed him how much scientific value can remain locked inside disconnected datasets. That insight ultimately shaped Ovation’s mission: to make high-quality, real-world patient data available when researchers, healthcare systems and life science organizations need it.


Episode Resources: Barry Wark on LinkedIn Ovation Website
Rowan Gardner on LinkedIn
PrecisionLife Website



Biology Matters is handcrafted by our friends over at: fame.so

Complex chronic conditions like ME/CFS and Long COVID routinely stall in clinical development. Traditional trial designs rely on broad diagnostic criteria, grouping biologically distinct patients together and drowning real drug efficacy signals in noise.

In this episode of Biology Matters, Steve Gardner speaks with Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation, about how the science around it is evolving, from metabolomics and patient stratification and how precision medicine could help move the field forward.


What You'll Learn:

• How Chris Armstrong first entered ME/CFS research through metabolomics
• Why metabolomics can help identify biological patterns and potential disease markers
• What the nitrogen hypothesis suggests about amino acid metabolism in ME/CFS
• Why ME/CFS and Long COVID are unlikely to be solved by one single treatment
• How patient stratification could improve clinical trial design
• Why drug repurposing may offer a faster route to potential treatments
• Why dosing and tolerability matter in frail or sensitive patient populations
• How better biological markers could help pharma, researchers and clinicians move forward
• Why the next five years could bring more useful tools and treatment insights for patients
  
  

About Steve

Steve Gardner is CEO and Co-Founder of PrecisionLife, recognised for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridges computational biology with clinical translation, positioning him at the forefront of precision medicine for complex chronic conditions, a space historically underserved by traditional approaches that have often focused more heavily on oncology. 

At PrecisionLife, Steve focuses on using better biological understanding to support earlier diagnosis, patient stratification and more targeted treatment development.


About Chris 

Chris Armstrong is Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Based at the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne, Chris has spent more than 15 years studying ME/CFS, with a particular focus on metabolomics, metabolic profiling and the biological mechanisms that may help explain the condition’s complex symptom patterns.

His research explores how metabolism, amino acid usage, nitrogen handling, heterogeneity and patient subgroups may shape ME/CFS and related conditions such as Long COVID. Chris’s work reflects a broader shift in the field: away from searching for one single explanation and toward understanding the different biological pathways that may be driving disease in different patients.


Episode Resources: Chris Armstrong on LinkedIn
Steve Gardner on LinkedIn
PrecisionLife Website


 Biology Matters is handcrafted by our friends over at: fame.so

Women’s health is often reduced to reproductive health, excluding the wider reality of how complex chronic diseases affect women across their lives. In this episode of Biology Matters, Rowan Gardner speaks with Dr. Veronique Bouchet, Chief Medical Officer at PrecisionLife, about the need to understand women’s health through a broader, biology-first lens. The conversation explores why diagnosis can be so difficult in overwhelmed healthcare systems, how clinicians are often working within pathways that were not designed around the complexity of women’s biology and how precision medicine can help solve the dearth of fast, accessible and non-invasive diagnostic tools that can help match patients to the right care earlier.


What You'll Learn:

• Why women’s health needs rethinking beyond reproductive medicine
• How common conditions such as depression, cardiovascular disease, autoimmune disease, migraine and Alzheimer’s disease affect women differently
• Why diagnostic delay is common in complex women’s health conditions such as endometriosis
• How incomplete biological data limits research, clinical trials and treatment development
• Why investment in women’s health has historically focused on too narrow areas of care
• Why better stratification can help clinicians, patients, pharma, biotech and healthcare systems move forward together
  
  

About Rowan 

Rowan Gardner is Chief Business and Investment Officer and Co-Founder of Precision Life, bringing 30+ years of experience across health tech, digital health, deep tech and biotech. Her expertise spans securing venture funding, building strategic partnerships and translating breakthrough science into real-world healthcare impact across multiple continents. Her insights into what leading health systems worldwide are doing differently provide actionable guidance for clinical leaders seeking to implement mechanism-based strategies that improve outcomes while reducing healthcare costs.

About Veronique 

Dr. Veronique Bouchet is Chief Medical Officer at PrecisionLife and a physician executive with more than three decades of international experience across biopharma, digital health, venture strategy and precision medicine. Her clinical background spans obstetrics, gynaecology, paediatrics and general medicine, giving her a broad view of the health challenges women face across adolescence, childbearing years, menopause and later life. Over the course of her career, Veronique has focused on translating scientific advances into practical patient impact, with a particular interest in complex chronic disease and women’s health.

Her work reflects the central belief that better understanding of biology can help healthcare move from broad symptom management toward earlier diagnosis, stratified treatment and more precise care.


Episode Resources: 

Veronique Bouchet on LinkedIn
Rowan Gardner on LinkedIn
PrecisionLife Website

 Biology Matters is handcrafted by our friends over at: fame.so

 Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, is a serious, life-altering disease that affects an estimated 17 – 24 million people worldwide, with many more living with ME-like symptoms following infections such as COVID. For patients and families, the impact can be enormous: persistent exhaustion, post-exertional malaise, pain, cognitive dysfunction, and in the most severe cases, being housebound, bedbound or unable to manage daily living tasks. And yet, awareness about what it is lags behind, let alone treatment options. 

In this episode of Biology Matters, Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained so under-recognised, despite its scale and severity. Sonya explains that the disease often makes people invisible, because those most affected may be too unwell to leave their homes, attend appointments, work, study or maintain social contact. The conversation explores the importance of advocacy, collaboration and patient involvement in changing that reality. 

What You'll Learn:

• What ME/CFS is and why post-exertional malaise is such a defining feature of the disease
• Why ME/CFS and ME-like symptoms after COVID affect such a large number of people
• How invisibility and isolation shape the patient experience
• Why advocacy for ME/CFS depends on listening, collaboration and persistence
• How patient involvement can make research stronger and more trusted
• Why the economic case for better ME/CFS research and care is so significant
• How the DecodeME study, LOCOME project, and precision medicine approaches are changing what is possible
• Why dedicated funding could accelerate diagnostics, drug repurposing and clinical progress
  
  

About Steve 

Steve Gardner is CEO and Co-Founder of PrecisionLife, recognized for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridging computational biology with clinical translation has positioned him at the forefront of precision medicine for complex chronic conditions. 
About Sonya 

Sonya Chowdhury is CEO of Action for ME, a UK charity working to improve the lives of children, adults and families affected by myalgic encephalomyelitis, also known as ME or ME/CFS. She works at the intersection of patient advocacy, public policy, research, fundraising and healthcare, helping build understanding of ME and improve recognition of the needs of people living with the disease. Her background in child protection social work has shaped her collaborative approach to advocacy, which is grounded in listening, partnership and championing the rights of people who are facing disadvantage, inequity and injustice. Through Action for ME, Sonya has helped keep patient experience at the centre of research, policy and public awareness, while supporting efforts to improve diagnosis, care, funding and scientific understanding for ME and related post-infectious conditions.


Episode Resources: 
Sonya Chowdhury on LinkedInAction for ME Website
Steve Gardner on LinkedIn
PrecisionLife Website


Biology Matters is handcrafted by our friends over at: fame.so

 Healthcare systems around the world are facing a difficult reality: more people are living longer, but with multiple chronic diseases that are expensive, difficult to manage, and usually diagnosed too late. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner, unpack why this isn’t just a medical challenge but a technology, leadership, and culture challenge.

What You'll Learn:

• The distinct hurdles healthcare faces compared to other industries when adopting technology.
• How culture, leadership, and communication shape successful healthcare transformation
• Why chronic disease is one of the biggest drivers of healthcare spending and system pressure
• Why earlier diagnosis and disease-modifying therapies are essential for long-term health
• Where AI can genuinely help healthcare (and where it cannot replace biological understanding)
• Why the future of healthcare depends on moving from reactive treatment to precision prevention

About Ray

Ray Pawlicki is Executive Chairman at PrecisionLife and a technology leader with decades of experience across life sciences, healthcare, consumer goods, financial services, and technology. He has held senior leadership roles at organizations including Novartis, Biogen, UMass Memorial Health, PepsiCo, Citibank, and Hewlett Packard.

Over the course of his career, he has worked closely with leadership to make technology and data central to the company’s transformation and lead major culture-change initiatives designed to support more collaborative, science-led, and data-driven ways of working. Today, Ray brings this cross-industry perspective to PrecisionLife, where he focuses on how technology, data, and precision medicine can help healthcare systems diagnose disease earlier, treat patients more effectively, and shift toward prevention.


About Steve

Steve Gardner is CEO and Co-Founder of Precision Life, recognized for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridging computational biology with clinical translation has positioned him at the forefront of precision medicine for complex chronic conditions - a space historically overlooked in favor of oncology-focused approaches. 


Episode Resources: 

Ray Pawlicki on LinkedInSteve Gardner on LinkedIn
PrecisionLife Website


Biology Matters is handcrafted by our friends over at: fame.so

 Healthcare systems around the world are under growing pressure from aging populations, rising costs and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the importance of answering the question “How do we prevent people from falling sick?”.

What You'll Learn:

• Why the Human Genome Project succeeded in cancer but stalled in chronic disease
• How to reframe chronic disease from a market problem to an economic opportunity
• The critical infrastructure gap preventing precision medicine deployment in chronic disease
• Why political and cultural incentives systematically favor treating symptoms over preventing disease
• How leading health systems (UAE, Singapore, integrated US systems) are building competitive advantage through data governance
• The immediate opportunity in women's health and rare conditions like ME/CFS and long COVID

Episode Resources: 

Steve Gardner on LinkedIn
Rowan Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people and account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. And the result is not just a scientific problem but a system-wide, society-wide healthcare crisis.

Hosted by Steven Gardner and Rowan Gardner of Precision Life, the podcast takes a different approach, starting with biology. Through conversations with healthcare executives, researchers, biotech leaders, and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions.

Each episode connects biological insight to real-world impact, from improving patient outcomes and reducing system inefficiencies to enabling more successful clinical trials and more precise treatment strategies.

If healthcare is to move from reactive treatment when we are sick to predictive, preventive, and personalized care, it will take a fundamental shift in how we understand disease. This podcast is about what that shift looks like and what it will take to make it happen.


Biology Matters is handcrafted by our friends over at: fame.so